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Abstract
Background: Gene co-expression network (GCN) mining is a systematic approach to efficiently identify novel
disease pathways, predict novel gene functions and search for potential disease biomarkers. However, few studies
have systematically identified GCNs in multiple brain transcriptomic data of Alzheimer’s disease (AD) patients and
looked for their specific functions.
Methods: In this study, we first mined GCN modules from AD and normal brain samples in multiple datasets
respectively; then identified gene modules that are specific to AD or normal samples; lastly, condition-specific
modules with similar functional enrichments were merged and enriched differentially expressed upstream
transcription factors were further examined for the AD/normal-specific modules.
Results: We obtained 30 AD-specific modules which showed gain of correlation in AD samples and 31 normal-
specific modules with loss of correlation in AD samples compared to normal ones, using the network mining tool
lmQCM. Functional and pathway enrichment analysis not only confirmed known gene functional categories related
to AD, but also identified novel regulatory factors and pathways. Remarkably, pathway analysis suggested that a
variety of viral, bacteria, and parasitic infection pathways are activated in AD samples. Furthermore, upstream
transcription factor analysis identified differentially expressed upstream regulators such as ZFHX3 for several
modules, which can be potential driver genes for AD etiology and pathology.
Conclusions: Through our state-of-the-art network-based approach, AD/normal-specific GCN modules were
identified using multiple transcriptomic datasets from multiple regions of the brain. Bacterial and viral infectious
disease related pathways are the most frequently enriched in modules across datasets. Transcription factor ZFHX3
was identified as a potential driver regulator targeting the infectious diseases pathways in AD-specific modules. Our
results provided new direction to the mechanism of AD as well as new candidates for drug targets.
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Background
Alzheimer’s disease (AD) is a slow progressing neurodegen-
erative disease, affecting about 40 million people worldwide
today. More than a century has passed since AD was first
identified, but the disease mechanism still remains unclear.
Till today, no curative treatment is available for AD [1].
The prevalent AD hypothesis is the “amyloid cascade” hy-
pothesis [1] proposed 25 years ago. This hypothesis sug-
gests that the abnormal accumulation of insoluble
β-amyloid (Aβ) peptide in cerebral plaques leads to neuro-
fibrillary tangles (NFT) by hyper-phosphorylated tau pro-
tein, which then triggers downstream inflammation
response, synapse loss, neuron death, and dementia. Al-
though Aβ and NFT are the two most prominent neuro-
pathologic features of AD, they are not unique to AD, and
it is still not clear whether they are the causes or the results
of AD or if there is causal relationship between the two [2].
AD-specific pathways, biological processes, and driver
genes remain to be found.
Since AD is a complex disease involving multiple bio-
logical processes, a systems biology approach is needed to
identify key pathways and genes for the development of
AD. Network-based approaches are commonly adopted in
systems biology [3]. In this paper, we apply a
co-expression network analysis on multiple transcriptomic
datasets of AD and normal brain samples to identify bio-
logical processes and potential driver or regulatory genes
specifically associated with or disrupted in AD. Currently,
most AD transcriptomic analysis studies are focusing on
identifying differential expressed genes from various brain
regions of AD patients [4, 5], and there are only few work
studied highly correlated pairs of genes to obtain gain or
loss of co-expression in AD [6].
The network mining algorithm used here is lmQCM [7],
which was developed by us to identify condition-specific
gene co-expression network (GCN) modules as a whole in
brains of AD patients as compared to normal controls and
look for potential “driver” regulators for AD. lmQCM has
been previously applied to disease-specific network mining
in several studies, and identified frequently co-expressed
modules in pan-cancer scale as well as in specific cancer
types and other diseases [8–10]. Unlike the widely used
WGCNA algorithm, which is based on hierarchical cluster-
ing, lmQCM allows modules to overlap with each other
and be capable of identifying smaller local gene modules
often induced by copy number variants [7]. As a result, we
identified 61 gene modules of distinct functional categories
with gain or loss of correlations in AD samples, many of
which have been linked to AD pathology while other are
new for AD. Remarkably, we found 9 enrichment terms
pertaining to infectious diseases in AD-specific modules
while the tight junction pathway was detected for a
normal-specific module, which supports the hypothesis that
brain infection may be the causes for AD. Moreover, we
conducted transcription factor analysis of the
condition-specific modules and discovered differentially
expressed upstream regulators for 16 gene modules that
are specific to AD or normal. Specifically, we identified
ZFHX3 as a key regulator for multiple infectious diseases
pathways which are highly enriched in AD-specific mod-
ules. This study made exciting discoveries of potential new
AD candidate driver genes and underlying pathways, there-
fore offers new insights and directions on mechanism and
drug design for AD.
Methods
Data and sample pre-processing
Two large microarray datasets GSE5281 [5] and
GSE48350 [6] from the NCBI Gene Expression Omnibus
(GEO) containing multiple regions of AD and normal
brains were downloaded, each with over 20 samples for
each specific brain region in each condition. Both data-
sets were generated using Affymetrix HU133 2.0 Plus
platform. An RNA-seq dataset was also obtained with
transcriptome-wide FPKM values for AD and normal
samples of multiple brain regions from the Allen Brain
Institute (http://aging.brain-map.org). In total, we proc-
essed 500 samples from 10 different brain tissues, of
which 197 samples are from 111 AD patients and 303
samples are from 97 healthy normal persons. The sam-
ple and dataset details are shown in Table 1. The two
microarray datasets were processed using R/Bioconduc-
tor package Affy [8] to generate normalized expression
values by RMA normalization using their default param-
eters. All datasets were pre-filtered to remove probes
without gene annotation, while for genes with multiple
probes, we followed the same procedure as in previous
studies [10, 11] to select the probeset with the highest
mean expression value. Only samples from patients diag-
nosed as “AD” or “Probable AD” were considered as AD
samples. Genes with more than 50% zero expression
levels across samples of AD or normal were removed
from all datasets. For the RNA-seq dataset, we kept
genes with FPKM value larger than 1 in at least one
sample. Before constructing the co-expression network,
all genes with variance in the bottom 20% percentile of
the entire transcriptome were discarded. The FPKM
values of the filtered genes were log2-transformed using
log2(FPKM + offset) with an offset = 1.0. After the filter-
ing, we obtained expression levels of 17,547 genes for
GSE5281, 16,686 genes for GSE48350 and 18,789 genes
for the Allen Brain Institute dataset. Since the samples
are post-mortem samples from confirmed AD patients
with pathological changes well-spread in the brain, we
aim to search for the gene modules commonly presented
in all of the AD-affected brain regions, therefore, we
combined samples from all brain regions for module
mining. For each dataset, t-test was used to identify the
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differentially expressed genes with a cut-off of statistical
significance p-value <0.05 and foldchange >1.5.
Gene co-expression network (GCN) construction and
module detection
We performed lmQCM network mining on each of the
3 pre-processed datasets separately. First, AD and nor-
mal samples were separated into different groups within
each dataset. Next, Pearson correlation coefficient (PCC)
between each pair of genes were calculated for AD and
normal samples separately. As a result, we obtained
weighted co-expression networks for AD and normal
samples respectively for each dataset, in which the nodes
are genes and the weights of the edges are PCC values.
Next, local maximized Quasi-Clique Merger (lmQCM)
previously developed by our group was applied to iden-
tify tightly co-expressed gene modules in the weighted
network [7]. It has been previously applied for bio-
marker prediction in multiple types of diseases including
colon, breast, lung cancers, leukemia, and Parkinson’s
disease as well as disease gene discovery [9–12]. The pa-
rameters for lmQCM were set as follows: t = 1.0, lambda
=1.0, gamma =0.3, beta =0.3,minimum cluster size =10.
The R package for this network mining tool is available
in CRAN as “lmQCM”, and the web-version is available
as well (https://apps.medgen.iupui.edu/rsc/tsunami/).
Comparison of modules detected by different GCN
algorithms
To compare our method with commonly used WGCNA,
we applied WGCNA to our datasets for GCN construc-
tion and module detection. We compared each module
identified by lmQCM to modules detected by WGCNA
with the same dataset. For each module identified by our
method, we obtained one matched module in WGCNA
modules, which showed the most gene overlapping. The
ratio of genes overlapped with matched WGCNA module
was calculated for each lmQCM module.
Test the robustness of lmQCM algorithm with Gaussian
noise simulated data
We tested the robustness of the lmQCM mining algo-
rithm in noisy data. For each dataset, we first introduced
additional 5, 10 and 15% of random Gaussian noise into
standardized expression data matrix (zero mean and unit
variance). Next, lmQCM modules were mined with the
same parameters as described previously for the same
three datasets with noise. The modules identified before
and after adding noise data were compared for
consistency by evaluating gene overlaps between experi-
ments. For each module, the ratios of overlapped genes
to original modules were calculated respectively in three
noise levels. Boxplots were generated for overlapping ra-
tios for the results from three noise level as compared to
original modules. Some modules may be exactly the
same before and after adding noise data, and these mod-
ules were counted.
Compare modules between AD and normal samples to
obtain condition-specific GCN modules
In order to determine if a gene module is condition spe-
cific, for each module detected in a specific condition (AD
or normal), we examined if the expression profiles of
genes in that module are significantly correlated in one
condition but not in the other with the previously devel-
oped metric Centered Concordance Index (CCI) [12]. CCI
values range from 0 to 1, which indicate the extent of
overall correlation of genes in a module. Larger CCI
values imply more densely correlated genes in that mod-
ule. We focused on the modules whose CCIs are signifi-
cantly high in one condition (after multiple-test
compensation) while not in the other. For a module con-
taining n genes, we randomly choose n genes from expres-
sion matrix and calculate the CCI. This procedure was
repeated 1000 times to obtain the CCI distribution. The
z-score (ZCCI) for the testing module CCI based on the
random sampling was calculated. This gives a measure-
ment on how significant is the observed CCI for the tested
gene module in the background of entire genome. For
each gene module in AD or normal samples, we calcu-
lated two CCIs, using the expression data from AD sam-
ples and normal samples separately, and the ZCCI are
calculated for each condition. Gene modules that are sig-
nificant (ZCCI ≤τ) in one condition but not significant
(ZCCI >τ) in the other are considered as condition-specific
modules. The threshold τ is determined based on the sig-
nificance requirement that τ is chosen such that the
one-tail p-value for the ZCCI is less than 0.05 for a specific
gene module. Additionally, certain modules contain
z-scores of opposite signs, which means the modules gain
correlation in one condition while losing correlation in
the other. For such cases, although p-values are less than
0.05 in both conditions, they are included for downstream
analysis due to the opposite change of correlations.
Table 1 Summrize of datasets we used in the analysis
Dataset Regions Total samples AD samples AD patients Normal samples Normal persons Subjects per person
GSE5281 6 161 87 23 74 13 1~12
GSE48350 4 253 80 58 173 28 1~8
Allen brain 4 86 30 30 56 56 1
Xiang et al. BMC Medical Genomics 2018, 11(Suppl 6):115 Page 41 of 112
Functional enrichment analysis
The R package Enrichr [13] was used to perform gene
ontology (GO) and pathway enrichment analysis of the
module genes identified from each of the three datasets.
“GO_Biological_Process_2017b” (BP) and “KEGG_2016”
databases were used. Only GO BP terms or KEGG path-
way with enrichment p-value less than 0.01 were consid-
ered significant enriched. Next, the frequencies of
specific GO/pathway terms were counted for AD and
normal specific modules respectively. Only GO terms
appeared in at least two of the three datasets were in-
cluded for further study. Redundant Gene Ontology
terms were merged by REViGO [14]. The workflow of
the entire analysis is shown in Fig. 1.
Upstream regulators identification
To search for upstream regulators of a module, Enrichr [13]
was used with the “TRANSFAC_and_JASPAR_PWMs”
database. The analysis with the database returns the tran-
scription factors (TFs) that regulate genes in the modules
(p-value <0.01). The frequencies of enriched TFs in AD spe-
cific or normal specific modules are also counted. Student’s
t-test (cutoff foldchange>1.5, p-value <0.05) was used to
check whether these transcription factors are differentially
expressed between AD and normal samples. Enriched TFs
that differentially expressed were retained as upstream regu-
lators of the modules. To further investigate the exact
enriched pathways or GO biological processes of the mod-
ules affected by the differentially expressed TFs, we com-
pared the targets of specific TFs that occurred in the
modules and its enriched functional term members. TFs
with more than two shared targets and enriched functional
term members of certain module are highlighted as most
significant upstream regulators.
Results
GCN modules specific to AD or normal brain tissues
We obtained 101 densely GCN modules from AD sam-
ples and 77 modules from normal samples in three data-
sets using the workflow (Fig. 1). To compare the
modules identified by our method with the popularly
used WGCNA [15], we also applied WGCNA to the
same datasets in our work to mine densely correlated
modules. Number of modules and module size range are
listed in Table 2 for both lmQCM and WGCNA method.
From the table, we can see that our method identifies
more modules with smaller sizes than WGCNA. For ex-
ample, for GSE48350 AD dataset, WGCNA returned 22
Fig. 1 Workflow to identify condition-specific co-expression modules and AD associated pathways and driver genes
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modules while our method gets 49 modules. The mod-
ule size range of WGCNA is 33~3567 while the modules
identified by our method ranges from 10~391. To check
if the genes in module identified by lmQCM are consist-
ent with WGCNA result, we compared the genes in
each module to modules of WGCNA. For example, in
GSE48350 AD dataset, for each module identified in
GSE48350 AD dataset by our method, we see a matched
module in WGCNA which showed the most gene over-
lapping. Over 73% of modules (36/49) of our method
shared over half of gene members with matched
WGCNA modules (Additional file 1: Table S1), which
indicates that the GCN modules from lmQCM are con-
sistent with the ones from WGCNA but tighter and
densely connected, often implying more specifically
enriched in biological processes.
We applied data pre-filtering to remove most of the
noise before module mining. However, to ensure our
lmQCM algorithm is robust under noisy condition, we
tested lmQCM robustness by introducing 5, 10 and 15%
of Gaussian random noise to the expression data before
applying lmQCM for module mining. Ratios of overlaps
between 178 original modules and modules obtained
after noise addition showed that the same or highly
overlapped modules were detected with even 15% of
Gaussian noise (Additional file 2: Figure S1). The aver-
age overlapping ratios are high (93.48, 88.83, and 85.31%
for 5, 10, and 15% of noise, respectively). In particular,
among 178 modules, 112, 78, and 72 of them are exactly
the same when introducing 5, 10, and 15% of noise.
These results demonstrate that lmQCM algorithm is
very robust under noisy condition.
Centered Concordance Index (CCI) [15] was used to
quantify the gain or loss of co-expression in AD vs, nor-
mal brains, for each module detected in a specific condi-
tion (i.e. AD or normal). First, we calculated CCI in both
AD and normal expression groups. Z-scores of CCI
(ZCCI) between the two conditions followed by
multiple-test compensation was used to determine if the
expression profiles of genes in the module are signifi-
cantly correlated in one condition but not in the other
(see Methods for details). This resulted in 30 AD specific
modules (AD_M1-AD_M30) and 31 normal specific
modules (N_M1-N_M31) for three datasets (see Add-
itional file 3: Table S2). The AD-specific modules
showed gain of connectivity or enhanced coregulation
between genes in AD samples and the normal specific
modules showed loss of connectivity or reduced coregu-
lation between genes in the module in AD samples
(Fig. 2a and b). The remaining 117 modules were as-
sumed to perform conserved functions across the AD
and normal conditions, therefore, we focused on the
condition-specific modules in the following analysis.
Frequent functional enrichment analysis of the condition-
specific GCN modules revealed functions associated with
AD pathology
The densely correlated modules are likely to be
co-regulated and perform similar functions. Genes in
AD specific modules gain correlation in AD relative to
normal condition while normal specific modules loss
correlation in AD as compared to normal condition.
These gene co-expression pattern change can be the in-
dication of the module genes functional change, which
potentially contributes to AD etiology and pathology.
Therefore, we conducted GO biological process and
pathway enrichment analysis for the 30 AD-specific
modules and 31 normal-specific modules. Figure 2
showed the gene expression correlation changes and
enriched pathways of an example normal-specific mod-
ule N_M4 from GSE4830 dataset, and AD-specific mod-
ule AD_M22 from GSE5281 dataset. Enriched pathways
for module N_M4 are complement and coagulation cas-
cades, focal adhesion, vascular smooth muscle contrac-
tion, tight junction, and cytokine-cytokine receptor
interaction. In AD-specific AD_M22, genes are enriched
in legionellosis, TNF signaling pathway, salmonella in-
fection, chemokine signaling pathway, NOD-like recep-
tor signaling pathway, malaria, AGE-RAGE signaling
pathway, and amoebiasis. All significant enriched GO
terms and pathways are summarized in Additional file 4.
Since the modules are from three independent tran-
scriptomic datasets each with different brain region
compositions, functional enrichment terms that
Table 2 Number of modules identified in three datasets and size range of the modules
Dataset Module number Module size range Module number Module size range
Method lmQCM lmQCM WGCNA WGCNA
GSE5281_AD 26 10~275 13 101~5438
GSE48350_AD 49 10~391 22 33~3567
Allen Brain_AD 26 10~145 29 34~3466
GSE5281_control 31 10~528 25 35~2657
GSE48350_control 32 10~176 20 34~3870
Allen Brain_control 14 10~106 13 40~4778
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occurred across modules from three datasets are more
possible to be prevalent to AD. Therefore, instead of
checking all GO terms of the modules, we focused on
GO terms that were significantly enriched in modules
from at least two datasets as frequently enriched GO
terms. As a result, we obtained 257 frequent enriched
GO terms (Enrichr p-value <0.01) for AD-specific mod-
ules and 162 such terms for normal-specific modules.
We further merged similar GO terms with the REVIGO
online tool [14]. In general, in both AD and
normal-specific modules, we found distinct GO BP
terms to each condition. As shown in Fig. 3a, most fre-
quently enriched GO BP terms in AD-specific modules
include response to interferon-alpha,response to mol-
ecule of bacterial origin,regulation of neuron death,
negative regulation of neural precursor cell proliferation,
neuron migration, cartilage development, skeletal system
development, and mitochondrial protein processing. The
normal specific modules are enriched for genes involved
in nervous system development, synapse assembly, regu-
lation of complement activation, transcription associated
regulation processes, and cell proliferation associated
processes. Many of these biological processes have previ-
ously been linked to AD-related changes [16–21]. For
example, Yokota et al. [18] identified the same enriched
GO biological processes about negative regulation of
gene expression. Zhang et al. [21] reported AD associ-
ated modules share enriched GO BP of extracellular
matrix, nervous system development, synaptic transmis-
sion, and neurotrophin signaling. Some of our enriched
GO terms are more specific, such as response to
interferon-alpha, response to molecule of bacterial ori-
gin, which is similar but more specific to immune re-
sponse reported in [21].Additionally, some of the
enriched GO biological processed identified here are
novel, such as cartilage development and skeletal system
development, which may infer potential new mecha-
nisms of AD pathology.
As for the KEGG pathway analysis, we obtained 60
enriched pathways in AD-specific modules and 47 in
normal-specific ones (Enrichr p-value <0.01). Among
the enriched pathways, 16 are common between
AD-specific modules and normal-specific modules, while
the remaining are specific to either AD or normal mod-
ules. We focused on the condition-specific pathways in
the following analysis. Certain enriched pathways fre-
quently occurr in the modules across three datasets as
well, so we computed the frequency of enriched pathway
terms in modules.
As shown in Fig. 3b, the AD-specific pathways include
metabolic associated pathways, bacterial and virus infec-
tions, cancer associated pathways, neuron associated
A
B
C
Fig. 2 Correlation heatmap of two example condition-specific modules and matched enriched pathway analysis of each module. a Correlation of
gene pairs in normal-specific N_M4 in normal samples (left) and in AD samples (right) b Correlation of gene pairs in AD-specific AD_M22 in
normal samples (left) and AD samples (right). c Top enriched pathways in normal-specific and AD-specific modules
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pathway, Hormone, various signaling pathway, PPAR
signaling pathway, regulation of actin cytoskeleton, and
non-alcoholic fatty liver disease (NAFLD). Remarkably,
although several previous studies have inferred immune
associated pathway such as immune response and
microglia pathway in AD samples [17, 21–23], we first
identified the specific infections pathway, termed Influ-
enza A, Measles, Hepatitis C, Herpes simplex infection,
and RIG-I-like receptor signaling pathway for AD spe-
cific modules. The normal-specific pathways include
GABAergic synapse and neuroactive ligand-receptor
interaction, amino acid metabolism, complement and
coagulation cascades, tight junction, platelet activation,
renin secretion, and RNA metabolism pathways. Among
which the tight junction, platelet activation and renin se-
cretion pathways are first identified compared to previ-
ous co-expression analysis of AD samples [17, 18, 21].
The more specific terms identified confirmed that our
method is able to discover more locally densely corre-
lated modules.
Pathways enriched in AD-specific modules that have
not been previously related to AD may represent novel
disease mechanisms and processes, which include, for
example, phospholipase D signaling pathway and
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osteoclast differentiation. Moreover, the comprehensive
representation of gene-gene interactions in the already
known AD-associated pathways can uncover novel gene
members, thus allowing us to examine known pathologic
mechanisms in more details.
Among these pathways, the most conspicuous ones in
AD-specific modules are infectious disease pathways. Infec-
tious disease pathways are identified in AD-specific mod-
ules from all three independent datasets, including module
AD_M9 in dataset GSE5281, module AD_M22 in
GSE48350 and module AD_M25 in the Allen Brain dataset.
The enriched infectious disease pathways include bacterial
infections such as African trypanosomiasis, legionellosis,
salmonella infection, parasitic infections like malaria, and
viral infections like Influenza A and Hepatitis C. In
normal-specific modules, the enriched tight junction path-
way in module N_M4 caught our attention. The genes in
the module that occurred in tight junction pathways are
RAB13, MYH11, MYL9, and YBX3. Genes in the module
enriched in tight junction are tightly correlated in normal
brain samples, where such correlation is lost in AD brain
samples. It suggests that the function of tight junction may
get disrupted in AD brains thus provide more access of
virus, bacteria, and even parasites into the brain.
Upstream transcription factor analysis for the infectious
disease pathways leading to discovery of ZFHX3 as a
potential driver regulator
To understand if there are key regulators for the biological
processes and pathways discussed above in AD, we
searched for upstream regulators among the modules by
performing regulatory transcription factor analysis to
identify gene interactions and regulatory elements within
each module, again using the Enrichr [13] package. Since
co-expression relationship is often resulted from
co-regulation, the pursuit of upstream regulators for the
condition specific GCN modules can lead to new insights
on the potential driver genes for AD or related symptoms.
As a result, 15 of 30 AD-specific modules and 22 of 31
normal specific ones were found to have enriched upstream
transcription factors (TFs). We then checked whether these
TFs are differentially expressed between AD and normal
samples. As a result, six AD-specific modules enriched with
eleven differentially expressed TFs and ten normal-specific
modules with 9 differentially expressed TFs were identified,
the details are shown in Tables 3 and 4. Here we observed
that AD-specific module AD_M1, module AD_M14, and
normal-specific module N_M9 are targeted by multiple TFs
while three TFs termed BCL6, JUND, and TCF4 are
enriched in two different normal-specific modules.
To further investigate the exact enriched pathways or
GO BP of the modules affected by the differentially
expressed TFs, we examined the targets of specific TFs
and their regulated pathways that are enriched in our
GCN modules (see Additional file 5). Among them,
AD-specific module AD_M1 is regulated by SP1, TEAD4,
PCBP1 with targets in the pathway of regulation of actin
cytoskeleton, cAMP signaling pathway, PI3K-Akt signaling
pathway, metabolic pathways, Alcoholism, and PPAR sig-
nalling pathway. AD-specific module AD_M3 is regulated
by JUN, which target genes enriched in the pathway in
cancer. AD-specific module AD_M25 is regulated by
ZFHX3, with target genes in infectious disease pathways.
For normal specific modules, JUND targets module
N_M9 which is enriched in GABAergic synapse, while
TCF4 targets genes both in enriched platelet activation
pathway of module N_M12 and enriched neuroactive
ligand-receptor interaction pathway of module N_M24.
ZBTB7A target genes in module N_M25 with respect to
osteoclast differentiation pathway.
What caught our interest is the transcription factor
ZFHX3 that targets AD-specific module AD_M25 which
are associated with infectious diseases from our enrich-
ment analysis. ZFHX3 is up-regulated in AD vs. normal
samples. The up-regulated TF ZFHX3 targets seven genes
in module AD_M25, where two genes OAS1 and RSAD2
are detected in infection pathways, and the other five
genes FAM122B, SAMD9, TRIM21, USP18 and IFIT3 are
also known to be related to infectious disease (Fig. 4). The
genes OAS1 and RSAD2 play important roles in infection
pathway, imposing an activation effect on several infec-
tious disease response pathways detected in AD compared
to normal samples. As for the other genes, SAMD9 has
been reported as an innate host antiviral stress response
element that participates in the formation of antiviral
granules [24]; TRIM21 was reported to promote response
to viral infections [25]; USP18 plays a role in innate im-
munity to viral infection [26, 27]; IFIT3 also involved in
antiviral functions according to previous research [28, 29],
and FAM122B is new here to be associated with infec-
tions. Previous research showed that genetic variants at
ZFHX3 is related to dementia [30]. In summary, the new
results provide exciting convergent evidences for the spe-
cific infection responses activated in AD. The potential
driver regulator roles of these pathways, particularly
ZFH3, should be further studied in AD.
Discussion
Genes in a co-expressed module share similar (i.e. corre-
lated) expression profiles in certain conditions and they are
often co-regulated by the same set of regulators (e.g. tran-
scription factors) or residing on proximal regions on the
chromosome. In addition, they often participate in related
biological processes. Thus, mining GCNs can lead to dis-
coveries in novel gene functions, protein-protein interac-
tions (PPI), key genetic regulators for diseases and biological
processes, functional structural variations, and disease bio-
markers. More importantly, by identifying condition specific
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GCN modules, we can identify potential “driver” regulators
for AD. Here we took advantage of the large amount of
publicly available transcriptome data from human AD stud-
ies and applied our network mining approach to identify
condition-specific GCN modules associated with AD. GCN
modules in AD have been studied previously. In Dua et al.
Table 3 Transcription factors enriched in AD-specific modules
that showed differentially expressed between AD and normal
brain samples
Differentially expressed
TFs
Module
name
TF target genes in the
module
FOS AD_M5 MED12;IL11;
GPR34;DOCK8;
MRC1;PLA2G7
JUN AD_M3 FBXW4;NOTCH4;
HDAC11;PLEKHB1;
ICAM2;CABLES1;
WDR83;GAB2;
PTH1R;FGF1;
AIF1L;TGFBR2;
TM7SF2;KIAA1598;
GNA12;PROM1;
KANK3;BOK;
TBC1D16
SP1 AD_M1 DDR1;SLC27A1;
LEPROT;MAOA;
HDAC11;NDRG2;
TRIM8;LFNG;
CCND3;ZNRF3;
NACC2;SH3PXD2B;
UAP1L1;PRDM16;
LRIG1;PLCG1;
ARHGEF40;NEO1;
RREB1;TBC1D16;
NKX2–2;MYO10;
PAX6;GRIN2C;
PRDX6;ERBB2IP;
ZFP41;RFX4;DLC1;
PPP1R1B;PLXNB1;
PLEKHO2;PPARA;
MEGF8;EZR;FGFR3
ZFHX3 AD_M25 FAM122B;RSAD2;
OAS1;SAMD9;
TRIM21;USP18;
IFIT3
ZNF281 AD_M1 DDR1;PPP1R14B;
ADCYAP1R1;PHLPP1;
SLC44A2;MAOA;
WFS1;PBXIP1;
NDRG2;TRIM8;
ERBB2IP;TUBB2B;
DLC1;TRPS1;NACC2;
PPP1R1B;PRDM16;
ITGA6;PLEKHO2;NEO1;
RREB1;GPR125;
RAPGEF3
TEAD4 AD_M1 ADCYAP1R1;LEPROT;
MAOA;AQP4;
NDRG2;NPAS3;
PHF21B;LFNG;
SOX2;CCND3;
SLC25A29;ZNRF3;
GNA12;SH3PXD2B;
UAP1L1;PLCG1;SOX9;
CCDC77;ARHGEF40;
NEO1;RREB1;
NKX2–2;SNTA1;PAQR6;
YES1;MYO10;WFS1;
C17ORF62;GRIN2C;
PRDX6;PLEKHA7;
GADD45G;KIAA1755;
ZFP41;FAM195B;
Table 3 Transcription factors enriched in AD-specific modules
that showed differentially expressed between AD and normal
brain samples (Continued)
Differentially expressed
TFs
Module
name
TF target genes in the
module
RFX4;DLC1;
PPP1R1B;PLEKHO2;
PPARA;MEGF8;EZR
MIB2 AD_M1 SLC27A1;ALDH1L1;
COL16A1;TTYH1;
PON2;MED12L;
EGFR;LFNG;
SLC25A29;HEPH;
PERP;NACC2;
SH3PXD2B;PHACTR3;
S100A13;KCNN3;
ACSS1;ARHGEF40;
PAMR1;RREB1;STOX1;
ZNF462;PPP1R14B;
SERPINB1;PAX6;
C17ORF62;PLEKHA7;
AIF1L;ZFP41;DLC1;
PMP22;MEGF8;SFXN5;
ITM2C
MEF2A AD_M12 NR4A2;TNMD;
GPR64;TMEM74;
SAMD3;TTN
PCBP1 AD_M1 DDR1;SLC27A1;
LEPROT;SDC4;
MAOA;AK4;NDRG2;
NPAS3;CCND3;
ZNRF3;NACC2;
SH3PXD2B;PRDM16;
UAP1L1;LRIG1;PLCG1;
ARHGEF40;NEO1;
RREB1;CD99;
TBC1D16;TMEM184B;
GPT2;PAX6;GRIN2C;
PRDX6;ERBB2IP;
GLUD1;FAM195B;
ZFP41;DLC1;
PLXNB1;PLEKHO2;
PPARA;MEGF8;
EZR;FGFR3;ZNF652
SMARCA2 AD_M14 FOXC2;SLC38A1;
FOXD2;CRABP2;
LRP1;CCDC25;
PLA2G2A;KCTD9;
KLF5;OS9;PPDPF;
P4HB;SLC22A8;
PHLDB2;PTGDR
STAT1 AD_M14 DSP;CLIC3;CRABP2;
LRP1;PRDM6;CXCR4;
BMP4;COL3A1;COL1A2;
PDLIM2;MLPH;NOV;
SLPI;SPTLC3;FRZB;
PPDPF;SLC26A7
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[31], network analysis of hippocampal gene expression data
of 22 AD patients showed enrichment of viral genome ex-
pression, glycogen catabolic process, triglyceride metabolic
process, cell death, and alcohol metabolic process. In Xia et
al. [32], by combining differential expression analysis and
GCN analysis, processes such as increased oxidative stress,
along with alterations in lipid metabolism in neurons have
been suggested to be associated with AD pathology. In Ding
et al. [33], an integrated approach based on multi-data fu-
sion on AD with the consideration of TF on the target gene
regulation led to discovery of transcription factors E2F4 and
ATF1 as well as immunoregulatory and neurogenesis pro-
cesses in AD pathology. In comparison, our analysis in-
volved much more samples, brain regions (see Table 1) and
three independent datasets. Besides AD samples, we in-
cluded normal samples in our analysis and identified
condition-specific modules, which are unique and differ
from those three works. The condition-specific modules re-
veal gain or loss correlation in AD compared to normal
samples. By linking the modules to its enriched biological
processes or pathways, we delineated pathways and gene
targets causally related to AD pathology in many respects.
Our results share some consistency with previous findings,
such as immune response related processes, but with more
details on the infectious pathways and potential regulators.
Many of the enriched GO terms for AD-specific mod-
ules have previously been reported to be associated with
AD [34–37]. For instance, the enrichment of regulation
of neuron death [38], negative regulation of neural pre-
cursor cell proliferation [39], and neuron migration [20]
may explain the neuronal death characteristic of AD.
The enrichment of mitochondrial protein processing is
no surprise either given that neurons rely heavily on the
functions of mitochondria and many research results
showed that dysfunction in mitochondria processes are
heavily involved in AD pathogenesis [40, 41].
The most interesting findings are the infectious diseases
pathways, which are detected in all three datasets. Other
pathways that have been implicated in AD are PPAR
signaling pathway, regulation of actin cytoskeleton,
Non-alcoholic fatty liver disease (NAFLD), and several sig-
naling pathways. In particular, enriched pathways in can-
cer are frequently detected in AD-specific modules among
three datasets, and as reported, there is an inverse rela-
tionship between cancers and AD [42, 43]. The biological
processes newly identified in this work that are not previ-
ously associated with AD are cartilage development and
skeletal system development, suggesting new insight and
hypothesis related to AD development.
The enriched biological processes and pathways in nor-
mal specific GCN modules, which are disrupted in AD
samples, varies substantially. Besides nervous system de-
velopment, synapse assembly, transcription, and cell pro-
liferation associated biological processes, GABAergic
synapse and neuroactive ligand-receptor interaction path-
ways are also disrupted in AD, which all fit the neuron de-
generation characteristic of AD well. Other pathways that
have effects on AD like tight junction [44–46] and platelet
activation [34] are also identified. Interestingly, genes in-
volved in tight junctions are only identified in
normal-specific modules (see Additional file 3), which in-
dicates that the dis-concordance of gene interaction in
AD may contribute to the loss of tight junctions in blood
brain barrier, which may in turn increase the chance of in-
fection in the brain of AD patients. The enrichment of
normal specific modules also revealed new pathways that
may have potential links to AD.
Immune responses were found in AD patients’
brain tissues years ago and vast evidence about it has
been accumulated [22, 23]. But how the immune
Table 4 Transcription factors enriched in normal-specific
modules that showed differentially expressed between AD and
normal brain samples
Differentially expressed
TFs
Module
name
TF target genes in the
module
BCL6 N_M9 CSRNP3;RBFOX2;UBE2R2;
THRAP3;NRXN1;OTUD7A;
FNIP2
BCL6 N_M13 TRPC3;RSPO2;BTBD11;
ITM2A;HS3ST1
JUND N_M9 GABRA1;CSRNP3;UBE2R2;
CCNY;NRXN1;GTPBP8;
RUNX1T1
JUND N_M30 CFH;C1S;MS4A4A;
TNFSF13B
REPIN1 N_M9 MYLIP;RBFOX2;CCNY;
RAB14;GABRA4;KLHL8;
KIF1A;SRCIN1
CBFB N_M11 DSP;CAMK2D;PTGER3;
ARHGAP6
TCF4 N_M12 CLEC3B;CD163;COL1A2;
SLC13A4;C7;C1S;
ADH1B;OGN;FBLN1;
CD14;CES1
TCF4 N_M24 GSTM3;SLC13A4;C2ORF40;
LRRC18;GOLM1;KCNJ13;
SERPINF1;TYRP1;ABCA4;
BUB1B;HTR2C;FBLN1;
SULF1;CLDN2;PRLR;
LOXL1;GHR;SLCO1B3;
SOSTDC1;OTX2;HPD
EGR1 N_M15 WWC3;CORO6;UPP1;
FRS3
SOX10 N_M23 RGS2;ALKBH5;SNX16;
BDNF;HS3ST2
ZBTB7A N_M25 EGR2;NR4A3;FOSB;
SIK1;FOS;JUNB
APEX1 N_M28 IGBP1;CLCN4;PHF20;
UBE2D3;ZNF12
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response is triggered is not clear. Recently, a surpris-
ing research showed that the accumulation of
Amyloid-β as hallmarks of the AD is a defense
mechanism and kills infectious agents including vi-
ruses or bacteria [47]. More recently, researchers
showed that there appeared to be much more bac-
teria in the AD patients’ brains than normal brains
by next-generation sequencing analysis [36]. It is
speculated that infections of common bacteria or
virus might be a potential cause of AD [36]. Consist-
ent with this notion, our results showed that
enriched infections pathways are frequently occurred
in AD-specific modules across all three independent
datasets we have analyzed, in AD_M9 for dataset
GSE5281, AD_M22 for GSE48350, and AD_M25 for
Allen Brain dataset. The infections pathways are re-
lated to African trypanosomiasis, Malaria, Hepatitis
B, and Hepatitis C (see Fig. 3). Moreover, we identi-
fied blood-brain barrier tight junction in
normal-specific modules, which implies that genes in
tight junction pathway lost their coordinated expres-
sion patterns in AD brain samples. It is widely ac-
knowledged that blood brain barrier prevents the
bacteria or virus from entering the brain [44]. The
dysregulated function of tight junction in the blood
brain barrier potentially allows the infectious agents
entering into the brain [44–46, 48]. Remarkably, in
addition to the gain and loss correlation of the spe-
cific modules, some of the expression levels of genes
in the infectious disease pathways are up-regulated
while all of the module genes in tight junction
pathway were down-regulated. Our findings not only
supported the idea of infection causing AD, but also
provided candidate GCN modules and genes in the
process.
As we know, biological processes or pathways may be
regulated by common upstream regulators. We performed
transcription factor analysis of these condition-specific
modules and discovered several differentially expressed
TFs like TEAD4, STAT1, and JUND that target some of
the modules as described in previous sections. The discov-
ery of these key upstream regulators complements the
pathways and provides new insights of the mechanism of
the disease development. We believe these upstream regu-
lators as the key regulatory genes of the modules could be
candidate driver genes of AD. In particular, for
AD-specific module AD_M25 enriched in infectious dis-
ease related pathways, we identified transcription factor
ZFHX3 as a potential driver regulator.
Conclusions
Our approach identified condition-specific GCN
modules using multiple expression datasets from AD
and normal multiple brain tissues. Frequently
enriched biological processes and pathways provide
strong evidences and new insights for AD related
pathways and potential AD driver genes. Our results
are consistent with recent findings of infection and
immune response frequently observed in AD brains,
but with more specific insights, which may provide
new direction to the mechanism of AD as well as
new candidates for therapeutic strategy for AD.
Fig. 4 The key upstream regulator identified by transcription factor analysis. ZFHX3 targets seven genes in module AD_M25. Most of the genes in
that module are associated with infectious disease, indicating the ZFHX3 as a key regulator of the module
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